Shannon Wu

Dr. Shannon Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
SWShannon Wu
Shannon Wu
FSFiras Sbeih
Firas Sbeih
SASamantha Anne
Samantha Anne
MCMichael S. Cohen
Michael S. Cohen
SSSeth Schwartz
Seth Schwartz
SASwathi Appachi
Swathi Appachi
Objective: To systematically review the literature to determine auditory outcomes of cochlear implantation in children ≤12 months old.Data Source: PubMed, EMBASE, Medline, CINAHL, Cochrane, Scopus, and Web of Science databases were searched from inception to 9/1/2021 using PRISMA guidelines.Review Methods: Studies analyzing auditory outcomes after cochlear implantation (CI) in children ≤12 months of age were included. Non‐English studies and case reports were excluded. Outcome measures included functional and objective auditory results. Two independent reviewers evaluated each abstract and article. Heterogeneity and bias across studies were evaluated.Results: Of 305 articles identified, 17 met inclusion criteria. There were 642 children ages 2 to 12 months at CI. The most common etiologies of hearing loss were congenital CMV, meningitis, idiopathic hearing loss, and GJB2 mutations and other genetic causes. All studies concluded that early CI was safe. Overall, outcomes improved following early CI: IT‐MAIS (9 studies), LittlEARS (4 studies), PTA (3 studies), CAP (3 studies), GASP (3 studies), and LNT (3 studies). Nine studies compared outcomes to an older implantation group (>12 months); of these (n = 450 early CI, n = 1189 late CI), 8 studies showed earlier CI achieved comparable or better auditory outcomes than later implantation, whereas 1 study (n = 120) concluded no differences in speech perception improvement.Conclusion: Auditory outcomes were overall improved in children ≤12 months old undergoing CI. Studies that compared early to late CI demonstrated similar or better auditory outcomes in early implantation group. Given the comparable safety profile and critical time period of speech and language acquisition, earlier CI should be considered for infants with hearing loss.

11 August 2022 in Blood
Verified
Journal Article
Open access
PDF file
SCSeunga Choo
Seunga Choo
FLFranziska K. Lorbeer
Franziska K. Lorbeer
SRSamuel G. Regalado
Samuel G. Regalado
SSSarah B. Short
Sarah B. Short
SWShannon Wu
Shannon Wu
DHDirk Hockemeyer
Dirk Hockemeyer
Mutations in the TINF2 gene, encoding the shelterin protein TIN2, cause telomere shortening and the inherited bone marrow (BM) failure syndrome dyskeratosis congenita (DC). A lack of suitable model systems limits the mechanistic understanding of telomere shortening in the stem cells and thus hinders the development of treatment options for BM failure. Here, we endogenously introduced TIN2-DC mutations in human embryonic stem cells (hESCs) and human hematopoietic stem and progenitor cells (HSPCs) to dissect the disease mechanism and identify a gene-editing strategy that rescued the disease phenotypes. The hESCs with the T284R disease mutation exhibited the short telomere phenotype observed in DC patients. Yet, telomeres in mutant hESCs did not trigger DNA damage responses at telomeres or show exacerbated telomere shortening when differentiated into telomerase-negative cells. Disruption of the mutant TINF2 allele by introducing a frameshift mutation in exon 2 restored telomere length in stem cells and the replicative potential of differentiated cells. Similarly, we introduced TIN2-DC disease variants in human HSPCs to assess the changes in telomere length and proliferative capacity. Lastly, we showed that editing at exon 2 of TINF2 that restored telomere length in hESCs could be generated in TINF2-DC patient HSPCs. Our study demonstrates a simple genetic intervention that rescues the TIN2-DC disease phenotype in stem cells and provides a versatile platform to assess the efficacy of potential therapeutic approaches in vivo.

1 May 2022 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
SWShannon Wu
Shannon Wu
KZKeren Zhou
Keren Zhou
AMAnita Misra-Hebert
Anita Misra-Hebert
JBJames Bena
James Bena
SKSangeeta Rao R Kashyap
Sangeeta Rao R Kashyap
Background: Hypertension, diabetes, and obesity are common comorbidities that portend worse outcomes due to coronavirus disease 2019 (COVID-19). Metabolic syndrome is the common denominator of these conditions. This study aims to characterize the association of metabolic syndrome and its surrogate biomarkers with severity of COVID-19 illness. Methods: This retrospective study included adult patients who tested for COVID-19 at an academic tertiary care institution between March 8, 2020, and May 17, 2020. Metabolic syndrome was defined by the modified World Health Organization criteria. Outcomes of hospitalization, intensive care unit (ICU) admission, and death were analyzed. Results: There were 23,282 patients who tested for COVID-19 and 3679 (15.8%) had a positive result. Of these, metabolic syndrome was present in 834 (39%) of 2139 patients with available data. Patients with metabolic syndrome tended to be older, male, African American, heavier, and with more comorbidities. Metabolic syndrome was associated with higher rates of hospital admission and death (P < 0.001). On multivariable analysis, patients with metabolic syndrome had an increased risk of 77% for hospitalization, 56% for ICU admission, and 81% for death (P < 0.001). High AST:ALT and TG:HDL-C ratios were associated with hospitalization and ICU admission, but not mortality. Conclusions: Patients with metabolic syndrome had significantly worse hospitalization and mortality rates due to COVID-19, even after adjusting for covariates. Targeting obesity, hyperglycemia, dyslipidemia, and hypertension could address modifiable risk factors to reduce mortality due to COVID-19.

1 June 2022 in Journal of Hand and Microsurgery
Verified
Journal Article
Closed access
PDF file
SWShannon Wu
Shannon Wu
MWMichael Wells
Michael Wells
MAMona Ascha
Mona Ascha
JGJames Gatherwright
James Gatherwright
KCKyle J. Chepla
Kyle J. Chepla
Objective This study aims to compare outcomes between Novosorb Biodegradable Temporizing Matrix (BTM) and Integra collagen-chondroitin silicone for upper-extremity wound reconstruction. Methods This retrospective study analyzed adult patients who underwent wound reconstruction with either BTM or Integra at our institution between 2015 and 2020. Results Forty-eight patients were included: 31 (64.6%) BTM and 17 (35.4%) Integra. Mean age was 44.0 (range: 18–68) years. Age, race, sex, smoking, comorbidities, and defect size were similar between groups. Wound etiologies included 12 (25.0%) burn, 22 (45.8%) trauma, and others. Median template size was 133 cm2 for BTM and 104 cm2 for Integra (p = 0.526). Skin grafting was performed after 14 (45.2%) and 14 (82.4%) wounds treated with BTM and Integra, respectively (p = 0.028). Template complications of infection and dehiscence were comparable. Skin-graft complications occurred in five (35.7%) and three (21.4%) wounds in BTM and Integra, respectively (p = 0.031). Skin-graft failure rates were comparable (p = 0.121). Mean number of secondary procedures required after template placement was higher in the Integra group (BTM, 1.0; Integra, 1.9; p = 0.090). Final healing was achieved in 17 (54.8%) BTM and 11 (64.7%) Integra wounds (p = 0.694). Median time to healing was 4.1 months after BTM and 2.6 months after Integra placement (p = 0.014). Conclusion Compared with Integra, BTM achieved comparable wound healing and complication rates. Fewer secondary procedures and skin grafts were observed in BTM wounds, likely as a result of the coronavirus disease 2019 pandemic. At our institution, 100 cm2 of product costs $850 for BTM and $3,150 for Integra, suggesting BTM as an economical alternative to fulfill the high functional and aesthetic requirements of upper-extremity wounds. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). For a retrospective study, formal consent is not required. M.A., K.C., and J.G. were responsible for conception and design; K.C. and J.G. were responsible for administrative support; K.C. and J.G. were responsible for the provision of study materials or patients; S.W. and M.W. were responsible for collection and assembly of data; S.W. and M.A. were responsible for data analysis and interpretation; all authors were responsible for manuscript writing; and all authors were responsible for final approval of manuscript. BMI, Body mass index BTM, Biodegradable Temporizing Matrix CCS, Collagen-chondroitin silicone EMR, Electronic medical record FDA, Food and Drug Administration IQR, Interquartile range SD, Standard deviation STSG, Split-thickness skin graft All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). No informed consent was required for this study. Informed consent was waived for all patients and no identifying patient information is in this article. Article published online: 01 June 2022 © 2022. Society of Indian Hand & Microsurgeons. All rights reserved. Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

18 January 2022 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SWShannon Wu
Shannon Wu
BCBonnie Chen
Bonnie Chen
CFChristopher W. Fleming
Christopher W. Fleming
ASAkeesha A. Shah
Akeesha A. Shah
CGChristopher C. Griffith
Christopher C. Griffith
JKJamie A. Ku
Jamie A. Ku

20 February 2023 in Head & Neck
Verified
Journal Article
Open access
SWShannon Wu
Shannon Wu
HHHanna Hong
Hanna Hong
MFMichael Fritz
Michael Fritz
JKJamie Ku
Jamie Ku
BPBrandon Prendes
Brandon Prendes
EMEric Lamarre MD
Eric Lamarre MD
Background: Resected oral cavity carcinoma defects are often reconstructed with osteocutaneous or soft‐tissue free flaps, but risk of osteoradionecrosis (ORN) is unknown.Methods: This retrospective study included oral cavity carcinoma treated with free‐tissue reconstruction and postoperative IMRT between 2000 and 2019. Risk‐regression assessed risk factors for grade ≥2 ORN.Results: One hundred fifty‐five patients (51% male, 28% current smokers, mean age 62 ± 11 years) were included. Median follow‐up was 32.6 months (range, 1.0–190.6). Thirty‐eight (25%) patients had fibular free flap for mandibular reconstruction, whereas 117 (76%) had soft‐tissue reconstruction. Grade ≥2 ORN occurred in 14 (9.0%) patients, at a median 9.8 months (range, 2.4–61.5) after IMRT. Post‐radiation teeth extraction was significantly associated with ORN. One‐year and 10‐year ORN rates were 5.2% and 10%, respectively.Conclusions: ORN risk was comparable between osteocutaneous and soft‐tissue reconstruction for resected oral cavity carcinoma. Osteocutaneous flaps can be safely performed with no excess concern for mandibular ORN.